Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Below 50 Day Moving Average of $4.71

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) shares passed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $4.71 and traded as low as $4.31. Vistagen Therapeutics shares last traded at $4.57, with a volume of 245,899 shares traded.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Jefferies Financial Group upgraded shares of Vistagen Therapeutics from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a report on Thursday, December 7th. William Blair restated an “outperform” rating on shares of Vistagen Therapeutics in a research note on Monday, December 4th.

Vistagen Therapeutics Stock Performance

The stock has a 50-day moving average price of $4.71 and a 200 day moving average price of $4.44.

Vistagen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings results on Tuesday, February 13th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.09. Vistagen Therapeutics had a negative net margin of 3,073.51% and a negative return on equity of 72.10%. The company had revenue of $0.41 million during the quarter, compared to analysts’ expectations of $0.73 million. Research analysts predict that Vistagen Therapeutics, Inc. will post -1.56 EPS for the current year.

Institutional Trading of Vistagen Therapeutics

A number of institutional investors have recently bought and sold shares of VTGN. Tower Research Capital LLC TRC acquired a new stake in shares of Vistagen Therapeutics during the 4th quarter worth about $48,000. Raymond James & Associates acquired a new stake in Vistagen Therapeutics during the third quarter worth approximately $52,000. Janney Montgomery Scott LLC purchased a new stake in shares of Vistagen Therapeutics during the 4th quarter worth approximately $51,000. Virtu Financial LLC acquired a new position in shares of Vistagen Therapeutics in the 4th quarter valued at $80,000. Finally, Citadel Advisors LLC grew its position in shares of Vistagen Therapeutics by 12.4% in the 2nd quarter. Citadel Advisors LLC now owns 19,871 shares of the company’s stock valued at $37,000 after buying an additional 2,197 shares during the last quarter. 78.39% of the stock is owned by hedge funds and other institutional investors.

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.